Genmab — Juli 2019
-
This D-IxaLendex trial fully recruited now at double the expected Enrollment https://clinicaltrials.gov/ct2/history/NCT03012880?A=11&B=12&C=merged#StudyPageTop
-
innovaTV 201 completed in April https://clinicaltrials.gov/ct2/history/NCT02001623?A=17&B=18&C=merged#StudyPageTop
-
the Dara Retreatment trial starts recruiting https://clinicaltrials.gov/ct2/history/NCT03871829?A=4&B=5&C=merged#StudyPageTop
-
Janssen advarer om dødelig bivirkning i patienter behandlet med Genmab-guldæg
Medicinalselskabet Janssen har opdaget, at behandling med det Genmab-udviklede kræftmiddel Darzalex muligvis kan føre til en reaktivering af hepatitis B-virus i tidligere smittede patienter. Selskabet har nu udsendt advarsler til alverdens sundhedsmyndigheder om bivirkningen, som i visse tilfælde har vist sig dødelig.
(medwatch.dk)
-
Måske er problemet eskaleret?
-
Hvorfor skulle Medwatch bringe det flere måneder senere?
-
Janssen omtaler problemet i denne patient-leaflet fra februar. https://www.janssen.com/australia/sites/www_janssen_com_australia/files/prod_files/live/darzalex_cmi.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind